A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology.
LAG-3 protein
anti-PD-L1
eftilagimod alpha
metastatic solid tumors
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
26
06
2023
revised:
28
07
2023
accepted:
31
07
2023
medline:
30
10
2023
pubmed:
25
9
2023
entrez:
24
9
2023
Statut:
ppublish
Résumé
Eftilagimod alpha (efti) is a major histocompatibility complex class II agonist activating antigen-presenting cells which leads to greater systemic type 1 T helper response and more cytotoxic CD8+ T-cell activation. This phase I trial evaluated the administration of efti, a soluble lymphocyte activation gene-3 (LAG-3) protein, combined with the anti-programmed death-ligand 1 (PD-L1) antibody avelumab in advanced solid tumors. Patients with heavily pretreated metastatic solid tumors received intravenous avelumab (800 mg) combined with subcutaneously administered efti (6 or 30 mg) for up to 12 cycles, followed by avelumab monotherapy. The primary endpoint was the assessment of the recommended phase II dose (RP2D) of efti in combination with avelumab. Twelve patients with different tumor entities were enrolled (six patients in each cohort). During treatment, no dose-limiting toxicities occurred, and the severity of most adverse events was grade 1 or 2. In total, nine serious adverse events were documented, resulting in a fatal outcome in two cases, but none of them were assessed to be treatment related. Five patients (42%) achieved partial response. The median progression-free survival was 1.96 months and the median overall survival was not reached, with a 12-month survival rate of 75%. Subcutaneously administered efti plus avelumab was well tolerated, and efti of 30 mg was determined to be RP2D. The activity is promising and warrants further investigation in future phase II trials.
Sections du résumé
BACKGROUND
Eftilagimod alpha (efti) is a major histocompatibility complex class II agonist activating antigen-presenting cells which leads to greater systemic type 1 T helper response and more cytotoxic CD8+ T-cell activation. This phase I trial evaluated the administration of efti, a soluble lymphocyte activation gene-3 (LAG-3) protein, combined with the anti-programmed death-ligand 1 (PD-L1) antibody avelumab in advanced solid tumors.
PATIENTS AND METHODS
Patients with heavily pretreated metastatic solid tumors received intravenous avelumab (800 mg) combined with subcutaneously administered efti (6 or 30 mg) for up to 12 cycles, followed by avelumab monotherapy. The primary endpoint was the assessment of the recommended phase II dose (RP2D) of efti in combination with avelumab.
RESULTS
Twelve patients with different tumor entities were enrolled (six patients in each cohort). During treatment, no dose-limiting toxicities occurred, and the severity of most adverse events was grade 1 or 2. In total, nine serious adverse events were documented, resulting in a fatal outcome in two cases, but none of them were assessed to be treatment related. Five patients (42%) achieved partial response. The median progression-free survival was 1.96 months and the median overall survival was not reached, with a 12-month survival rate of 75%.
CONCLUSION
Subcutaneously administered efti plus avelumab was well tolerated, and efti of 30 mg was determined to be RP2D. The activity is promising and warrants further investigation in future phase II trials.
Identifiants
pubmed: 37742484
pii: S2059-7029(23)00858-X
doi: 10.1016/j.esmoop.2023.101623
pmc: PMC10594027
pii:
doi:
Substances chimiques
avelumab
KXG2PJ551I
CD274 protein, human
0
B7-H1 Antigen
0
Antibodies, Monoclonal
0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101623Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Future Oncol. 2019 Jun;15(17):1963-1973
pubmed: 30977393
Front Oncol. 2020 Jun 30;10:1049
pubmed: 32714866
JCI Insight. 2019 Mar 7;4(5):
pubmed: 30721155
J Immunother Cancer. 2019 Feb 4;7(1):30
pubmed: 30717797
J Immunol. 2007 Sep 15;179(6):4202-11
pubmed: 17785860
Ann Oncol. 2018 Oct 1;29(10):2052-2060
pubmed: 30052729
J Immunol. 2008 Mar 15;180(6):3782-8
pubmed: 18322184
Lancet Oncol. 2017 May;18(5):599-610
pubmed: 28373005
Vaccine. 2006 Jun 29;24(26):5426-33
pubmed: 16621192
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33755718
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Blood. 2003 Sep 15;102(6):2130-7
pubmed: 12775570
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Immunother Cancer. 2019 Oct 24;7(1):275
pubmed: 31651359
J Exp Med. 1992 Aug 1;176(2):327-37
pubmed: 1380059
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Leukoc Biol. 2006 Dec;80(6):1434-44
pubmed: 16980511
J Immunol. 2007 Feb 15;178(4):2278-86
pubmed: 17277133
JAMA Netw Open. 2018 Jun 1;1(2):e180416
pubmed: 30646078
Clin Cancer Res. 2009 Oct 1;15(19):6225-31
pubmed: 19755389
Front Oncol. 2021 Aug 30;11:710286
pubmed: 34527583
J Thorac Oncol. 2021 Aug;16(8):1369-1378
pubmed: 33845211
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33037118
Gastric Cancer. 2021 Jul;24(4):946-958
pubmed: 33743112
Br J Cancer. 2016 Aug 23;115(5):553-63
pubmed: 27490802
Adv Pharmacol. 2021;91:111-139
pubmed: 34099106
J Transl Med. 2010 Jul 23;8:71
pubmed: 20653948
Gynecol Oncol. 2019 Oct;155(1):51-57
pubmed: 31421916
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Nature. 2017 Nov 23;551(7681):517-520
pubmed: 29132144
Liver Cancer. 2021 Jun 30;10(5):500-509
pubmed: 34721511
Pharmaceutics. 2022 Jun 10;14(6):
pubmed: 35745800
J Immunol. 2002 Apr 15;168(8):3874-80
pubmed: 11937541
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Expert Opin Biol Ther. 2017 Apr;17(4):515-523
pubmed: 28274143
Trends Immunol. 2015 Apr;36(4):250-6
pubmed: 25758021